Nayiyuan Wu

4.7k total citations · 5 hit papers
84 papers, 2.9k citations indexed

About

Nayiyuan Wu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Nayiyuan Wu has authored 84 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Molecular Biology, 35 papers in Cancer Research and 17 papers in Oncology. Recurrent topics in Nayiyuan Wu's work include Cancer-related molecular mechanisms research (20 papers), RNA modifications and cancer (20 papers) and Ovarian cancer diagnosis and treatment (12 papers). Nayiyuan Wu is often cited by papers focused on Cancer-related molecular mechanisms research (20 papers), RNA modifications and cancer (20 papers) and Ovarian cancer diagnosis and treatment (12 papers). Nayiyuan Wu collaborates with scholars based in China, Taiwan and United States. Nayiyuan Wu's co-authors include Qianjin Liao, Yujuan Zhou, Linda Oyang, Jing Wang, Longzheng Xia, Yanyan Tang, Shiming Tan, Jinguan Lin, Zhaoyi Liu and Yaqian Han and has published in prestigious journals such as Oncogene, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Nayiyuan Wu

76 papers receiving 2.8k citations

Hit Papers

The cancer metabolic reprogramming and immune response 2020 2026 2022 2024 2021 2020 2021 2023 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The cancer metabolic reprogramming and immune response
    2021 799 citations Longzheng Xia, Linda Oyang et al. Molecular Cancer profile →
  2. PARP inhibitor resistance: the underlying mechanisms and clinical implications
    2020 344 citations Nayiyuan Wu et al. Molecular Cancer profile →
  3. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer
    2021 252 citations Nayiyuan Wu et al. profile →
  4. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential
    2023 121 citations Xuemeng Xu, Peng Qiu et al. Experimental & Molecular Medicine profile →
  5. Endoplasmic reticulum stress—a key guardian in cancer
    2024 62 citations Wenlong Zhang, Yidan Shi et al. Cell Death Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nayiyuan Wu China 24 1.7k 1.1k 742 557 426 84 2.9k
Germana Castelli Italy 29 1.6k 0.9× 950 0.9× 798 1.1× 478 0.9× 400 0.9× 97 3.1k
Seung-Oe Lim United States 15 1.8k 1.0× 969 0.9× 1.6k 2.2× 546 1.0× 843 2.0× 17 3.4k
Xin Dong China 29 1.9k 1.1× 986 0.9× 849 1.1× 799 1.4× 548 1.3× 75 3.0k
Katherine M. Aird United States 29 2.1k 1.2× 658 0.6× 659 0.9× 200 0.4× 406 1.0× 58 3.0k
Yue Wang China 26 1.1k 0.6× 753 0.7× 914 1.2× 282 0.5× 469 1.1× 117 2.3k
Paweł Surowiak Poland 32 2.3k 1.3× 930 0.9× 1.3k 1.7× 622 1.1× 356 0.8× 97 3.7k
Vijay Pandey China 30 1.4k 0.8× 706 0.7× 658 0.9× 226 0.4× 281 0.7× 105 2.5k
Meidan Ying China 34 2.2k 1.3× 813 0.8× 705 1.0× 575 1.0× 493 1.2× 95 3.3k

Countries citing papers authored by Nayiyuan Wu

Since Specialization
Citations

This map shows the geographic impact of Nayiyuan Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nayiyuan Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nayiyuan Wu more than expected).

Fields of papers citing papers by Nayiyuan Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nayiyuan Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nayiyuan Wu. The network helps show where Nayiyuan Wu may publish in the future.

Co-authorship network of co-authors of Nayiyuan Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Nayiyuan Wu. A scholar is included among the top collaborators of Nayiyuan Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nayiyuan Wu. Nayiyuan Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tang, Haoneng, Peng Qiu, Linda Oyang, et al.. (2025). Fusion genes in cancers: Biogenesis, functions, and therapeutic implications. Genes & Diseases. 12(5). 101536–101536.
2.
Qiu, Peng, Lujuan Wang, Ying Long, et al.. (2025). SRSF9 mediates oncogenic RNA splicing of SLC37A4 via liquid–liquid phase separation to promote oral cancer progression. Journal of Advanced Research. 79. 505–520. 3 indexed citations
3.
Xu, Xuemeng, Peng Qiu, Yaqian Han, et al.. (2025). CircRNF13 enhances IGF2BP1 phase separation-mediated ITGB1 mRNA stabilization in an m6A-dependent manner to promote oral cancer cisplatin chemoresistance. Molecular Cancer. 24(1). 36–36. 8 indexed citations
4.
Tan, Shiming, Shizhen Li, Longzheng Xia, et al.. (2025). Long non‑coding RNA ABHD11‑AS1 inhibits colorectal cancer progression through interacting with EGFR to suppress the EGFR/ERK signaling pathway. International Journal of Oncology. 66(3). 1 indexed citations
5.
Han, Yaqian, Shizhen Li, Linda Oyang, et al.. (2025). Novel insights into lncRNAs as key regulators of post-translational modifications in cancer: mechanisms and therapeutic potential. Cellular Oncology. 48(5). 1219–1244. 1 indexed citations
6.
Xuan, Li, Nayiyuan Wu, Xiu Zhang, et al.. (2025). Calcium-iron crosstalk in epileptogenesis: Unraveling mechanisms and therapeutic opportunities. Neurobiology of Disease. 212. 106989–106989. 1 indexed citations
7.
Qiu, Peng, Xuemeng Xu, Wenlong Zhang, et al.. (2025). Crosstalk between RNA-binding proteins and non-coding RNAs in tumors: molecular mechanisms, and clinical significance. International Journal of Biological Sciences. 21(7). 2991–3010. 3 indexed citations
8.
Jiang, Xianjie, Qiu Peng, Mingjing Peng, et al.. (2024). Cellular metabolism: A key player in cancer ferroptosis. Cancer Communications. 44(2). 185–204. 36 indexed citations
9.
Jiang, Xianjie, Mingjing Peng, Qiang Liu, et al.. (2024). Circular RNA hsa_circ_0000467 promotes colorectal cancer progression by promoting eIF4A3-mediated c-Myc translation. Molecular Cancer. 23(1). 151–151. 13 indexed citations
10.
Cao, Si, Xiaoyi Zhang, Chao Fang, et al.. (2024). Mendelian Randomization Study Supports Genetic Liability to Obsessive–Compulsive Disorder Associated With the Risk of Alzheimer's Disease. Brain and Behavior. 14(10). e70081–e70081.
11.
Zhang, Wenlong, Yidan Shi, Linda Oyang, et al.. (2024). Endoplasmic reticulum stress—a key guardian in cancer. Cell Death Discovery. 10(1). 343–343. 62 indexed citations breakdown →
12.
Xia, Longzheng, Jinguan Lin, Mingjing Peng, et al.. (2024). Diallyl disulfide induces DNA damage and growth inhibition in colorectal cancer cells by promoting POU2F1 ubiquitination. International Journal of Biological Sciences. 20(4). 1125–1141. 8 indexed citations
13.
Li, Handong, et al.. (2024). Predicting progression-free survival in patients with epithelial ovarian cancer using an interpretable random forest model. Heliyon. 10(15). e35344–e35344. 3 indexed citations
14.
Xu, Xuemeng, Peng Qiu, Xianjie Jiang, et al.. (2023). Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential. Experimental & Molecular Medicine. 55(7). 1357–1370. 121 indexed citations breakdown →
15.
16.
Wu, Nayiyuan, Danyan Zhu, Xing Li, et al.. (2023). CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma. Journal of Endocrinological Investigation. 46(8). 1573–1587. 14 indexed citations
17.
Qiu, Peng, Yujuan Zhou, Linda Oyang, et al.. (2021). Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. Molecular Therapy. 30(3). 1018–1035. 44 indexed citations
18.
Fang, Chao, Xiangping Li, Yixin Chen, et al.. (2018). Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response. Journal of Thoracic Disease. 10(6). 3329–3340. 13 indexed citations
19.
Wu, Nayiyuan, Hsuan-Shun Huang, Tung Chao, et al.. (2017). Progesterone Prevents High-Grade Serous Ovarian Cancer by Inducing Necroptosis of p53-Defective Fallopian Tube Epithelial Cells. Cell Reports. 18(11). 2557–2565. 58 indexed citations
20.
Fang, Chao, Yixin Chen, Nayiyuan Wu, et al.. (2017). MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway. Scientific Reports. 7(1). 40384–40384. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Germana Castelli Breakdown of academic impact, for papers by Seung-Oe Lim Breakdown of academic impact, for papers by Xin Dong Breakdown of academic impact, for papers by Katherine M. Aird Breakdown of academic impact, for papers by Yue Wang Breakdown of academic impact, for papers by Paweł Surowiak Breakdown of academic impact, for papers by Vijay Pandey Breakdown of academic impact, for papers by Meidan Ying
Rankless by CCL
2026